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ORIGINAL ARTICLE
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Abstract
The aim was to determine disease-causing variants in the GALT gene which codes for
the enzyme galactose-1-phosphate uridylyltransferase. Loss of activity of this enzyme
causes classical galactosemia—a life threatening, treatable disorder, included in the
Swedish newborn screening program since 1967. A total of 66 patients with the disease are known in Sweden and 56 index patients were investigated. An additional two
patients with Duarte galactosemia were included. The disease-causing variants were
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identified in all patients. As reported from other countries only a few variants fre-
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are found in one to three patients each. The most common variant, p.(Gln188Arg), has
an allele frequency of 51% in the cohort. A total of 16 novel variants were found

Communicating Editor: Jaak Jaeken
Funding information
Karolinska Institutet, Grant/Award Number:
KI-fonder; Stockholms Läns Landsting,
Grant/Award Number: ALF

quently recur in severe disease. The two variants p.(Gln188Arg) (c.563A>G) and p.
(Met142Lys) (c.425T>A) are present in several index patients whereas the remaining

among the 33 different variants in the cohort. Two of these are synonymous variants
affecting splicing, demonstrating the importance of the evaluation of synonymous variants at the cDNA level. Concise sentence: Galactosemia is a rare disease in Sweden
and the disease-causing variants are heterogenous including two synonymous variants.
KEYWORDS
galactosemia, genetics, mutations, neonatal screening, newborn screening

1 | INTRODUCTION
Galactosemia is a group of autosomal recessive disorders: galactokinase deficiency (OMIM #230200), galactose-1-phosphate
uridylyltransferase deficiency (OMIM #230400, GALT deficiency), galactose epimerase deficiency (OMIM #230350) and
the recently discovered galactose mutarotase deficiency
(GALM, OMIM #137030)1 affecting the metabolism of galactose (Gal). The most common form is GALT deficiency
resulting in an accumulation of Gal, galactose-1-phosphate
(Gal-1-P), galactitol and galactonate.2
The disease is potentially lethal if not treated early with a
Gal-restricted diet. Early diagnosis by newborn screening
1008
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(NBS) has improved the prognosis for patients. Long-term
complications ranging from mild speech and language delay
to more severe mental difficulties and neurological defects
are not uncommon, and a high proportion of affected women
have primary ovarian insufficiency.3,4
Patients with a milder form of galactosemia are most often
compound heterozygous for one severe, classical variant (G),
and the milder, Duarte variant (D), p.(Asn314Asp) (c.940A>G).
The p.(Asn314Asp) variant results in a residual activity of 50%
when it is found in cis with the four-base deletion, c.-119_116delGTCA in the promoter region, and the three intron variants c.378-27G>C, c.507+62G>A and c.508-24G>A.5 This
combination of cis Duarte variants is well known and is found in
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most studied populations. Patients with D/G are often detected
in NBS programs due to a GALT activity of approximately 25%
of normal.6 Although there is an uncertainty whether these
patients need treatment, there are several publications indicating
a favorable outcome for D/G patients without treatment with a
Gal-restricted diet.7-9
The first screening method described was a bacterial inhibition assay,10 followed by the Beutler enzyme spot test.11 The
current methods employed by screening laboratories either
measure the activity of the GALT enzyme (EC 2.7.7.12)
and/or the amount of total Gal (Gal and Gal-1-P).12 Galactosemia screening, including all three enzyme deficiencies, was
added to the Swedish NBS program in 1967.13 The Beutler
test was implemented in Sweden in 1986, and since then, the
program only detects patients with GALT deficiency. The
recall levels were adjusted in 1992 to minimize the detection
of infants with the D/G variant.14
The Swedish NBS program is centralized to one laboratory,
in Stockholm, with approximately 120 000 babies screened
annually. Centralization of the screening facilitates record retention of all recalled cases, true as well as false positive. The fact
that all Swedish citizens have a unique personal identification
number, minimizes the risk that patients are lost to follow up.
The screening laboratory is part of the Centre for Inherited
Metabolic Diseases at Karolinska University Hospital, Stockholm, one of two Swedish laboratories performing biochemical and molecular diagnostics of inborn errors of metabolism.
This includes molecular genetic investigations, determination
of GALT activity in erythrocytes, analysis of Gal and Gal-1-P
in dried blood spots (DBS) and galactitol in urine.
The first sequence variants, causing classical galactosemia,
were reported in 1991.15,16 The most cited variants in Caucasians are p.(Gln188Arg) (c.563A>G) and p.(Lys285Asn)
(c.855G>T), while p.(Ser135Leu) (c.404C>T) is common
among patients of African origin. These three variants account
for more than 80% of all affected alleles reported.17 Patients
harboring the variant p.(Ser135Leu) have absent GALT activity in erythrocytes, but approximately 10% residual activity in
tissues such as liver, intestine and leukocytes, resulting in a
milder clinical picture.18
Here we present the spectrum of GALT variants in the
Swedish galactosemia population, including 16 variants not
reported to HGMD Professional 2018.3 (HGMD) or the
ARUP GALT database, (http://www.arup.utah.edu/database/
galt/GALT_display.php, accessed 22 October 2018).19
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have been diagnosed with severe GALT deficiency (GALT
activity <1% of normal) and five (two males) with mild GALT
deficiency (GALT activity between 3% and 25% of normal
and normal excretion of galactitol in urine from age 1 year).
An additional nine patients (seven males) with classical galactosemia are known in the country: three patients diagnosed
before the onset of screening and six in their home countries.
All galactosemia patients in Sweden, except one were
screened for GALT variants in this or a previous study.20
The genetic study enrolled index cases from 56 families
(32 males): age 1-54, median 25.8 years. Of these families,
eight have more than one child with galactosemia. An additional two patients with Duarte galactosemia, are included.
The patients detected by NBS, were diagnosed at an average
age of 8 days (range 3-14 days) before 2008, and at an average
age of 4 days (range 3-6 days) from 2008, onwards. In 2008 the
sampling time was moved from as soon as possible after
72 hours to as soon as possible after 48 hours of age.14
Genotyping is part of the clinical diagnostic routine for
patients with galactosemia. Variants were confirmed in both
parents of 60% (34/56) of the patients.
The project was approved by the Regional Ethical Committee of Stockholm (2008/351-31).

3 | ANALYSIS OF THE GALT G ENE
3.1 | DNA-sequencing
Genomic DNA was isolated from whole blood with QIAamp
DNA blood mini/midi kit (QIAGEN, Venlo, The Netherlands). Search for variants was performed by Sanger sequencing of the promoter, exons and intron-exon flanking regions in
eight fragments. Out of the 11 exons, 3-4, 5-6 and 8-9 were
sequenced together. Direct-cycle sequencing of all PCR fragments was performed with BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA) following the manufacturer's recommendations. Nomenclature for
variants follows the guidelines and recommendations of the
Human Genome Variation Society (http://www.HGVS.org/
varnomen)21 and novel variants were validated using the
Mutalyzer program (https://mutalyzer.nl/). cDNA numbering
commences from the ATG start codon, where +1 is the A of
the ATG translation initiation codon (NM_00155.3). Novel
variants have been submitted to ARUP GALT database.

3.2 | Reverse transcription-PCR (RT-PCR)
2 | M A T E R I A L AN D M E T H O D S
2.1 | Patients
As at 31 December 2018, 5 331 800 newborns have been
screened for galactosemia. Of these, 52 patients (29 males),

The influence of identified novel variants on mRNA splicing
was studied by amplification of the segment containing the
appropriate exons by RT-PCR. Total mRNA was extracted
from whole blood using the PAXgene Blood RNA Kit
(Qiagen GmbH, Hilden, Germany) or from fibroblasts. First
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strand cDNA was synthesized from isolated mRNA using
iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc.). To
confirm the aberrant splicing, cDNA fragments were amplified, using primers covering the area of interest. Amplified
products were separated by agarose gel electrophoresis and
visualized by gel red staining, GelRed, (Biotium Inc., Fremont, CA). Direct-cycle sequencing of the PCR fragments of
interest, was performed with BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA).

3.3 | Bioinformatic analysis
The bioinformatic tools, Polymorphism Phenotyping v2
(PolyPhen-2 v2)22 and Protein Variation Effect Analyzer
(Provean v1.1.3),23 were used for the prediction of the pathogenicity of unpublished nonsynonymous missense variants,
and Berkeley Drosophila Genome Project (BDGP)24 was used
for synonymous missense variants, splice site variants and
intronic variants. Allele frequencies were obtained from
Genome Aggregation Database (GnomAD), (http://gnomad.
broadinstitute.org, accessed 15 May 2019). GALT variants
were considered novel if not described in HGMD or the
ARUP GALT database. All variants were checked against the
Database of single nucleotide polymorphisms (dbSNP, https://
www.ncbi.nlm.nih.gov/snp, accessed 22 October 2018).

3.4 | Biochemical analysis
25

Gal and Gal-1-P were quantified in DBS. The detection
limit at our laboratory was 0.1 mmol/l (reference value
<0.1 mmol/l) for both analytes.
Galactitol was determined using GC-MS according to
Allen with modifications.26 The detection limit was 20 μmol/l
(reference value controls, n = 24, <200 mmol/mol creatinine).
GALT activity was measured in erythrocytes with 14Clabeled Gal-1-P substrate27 after an incubation time of 1 hour
(reference value controls, n = 48, 10.4 μkat/kg Hb, range
7.0-13.1 μkat/kg Hb). In patients with possible residual
activity, the GALT activity was measured with incubation
times of 1 and 2 hours. To evaluate if prolonged incubation
in the Beutler test could be an alternative for the determination of low GALT activity in erythrocytes, samples from
patients were incubated for 3 and 6 hours in the Beutler test.

verified by restriction fragment length polymorphism. The
remaining four patients were reinvestigated in this study.
Only data from index cases are included. In addition, two
patients with Duarte galactosemia and novel variants are
included. The disease-causing variants were detected in all
patients and 33 different GALT variants were identified (Table 1).
Nineteen patients were homozygous and 17 heterozygous
for the most common variant, p.(Gln188Arg). The second
most frequent variant was p.(Met142Lys) (c.425T>A), with
an allele frequency of 9%. Six patients were compound heterozygous for p.[(Met142Lys)];[(Gln188Arg)], making it the second most common genotype. Only three additional, known
variants were found in more than one patient: p.(Leu195Pro)
(c.584T>C) (n = 2), p.(Lys285Asn) (n = 3), p.(Arg333Trp)
(c.997C>T) (n = 2) and c.508-29delT (n = 2).
A total of 16 novel variants were identified, each in only
one patient, except for the two variants: p.(Leu37Arg)
(c.110T>G) and p.(Pro109=) (c.327A>G), which were
found in two patients (Table 1).
Nineteen patients carry genotypes not described before.
Of these, 13 are associated with severe galactosemia, four
with a milder disease and two are associated with the D/G
disease (Table 2).

4.2 | Prediction of pathogenicity of novel
missense variants
All nonsynonymous missense variants were analyzed with the
bioinformatic tools PolyPhen-2 v2 and Provean (Table 1).
Three novel variants were classified as benign in both tools.
The in silico predictions for these variants are in agreement
with the phenotypes of the patients. Four novel variants were
considered deleterious by both tools and the clinical presentation of the patients supported these predictions.
For the novel variant p.(Ala46Val) (c.137C>T), the predictions were inconclusive. PolyPhen-2 considered the variant “Possibly damaging” while Provean considered it
“Neutral.” This variant was detected in a patient who is compound heterozygous for p.(Ala46Val)(;)(Asn314Asp) and
diagnosed as D/G. The patient has a GALT activity of 25%
of normal, and the p.(Ala46Val) is therefore considered a
variant associated with severe galactosemia.

4.3 | p.(Arg25Pro)
4 | RESULTS
4.1 | Molecular analysis
The search for GALT variants in the Swedish galactosemia
population was initiated in the beginning of the 1990s.20
From a total of nine patients, five were fully characterized.
These patients were homozygous for p.(Gln188Arg), as

The variant p.(Arg25Pro) (c.74G>C) was found in combination with p.(Gln188Arg). The screening sample taken at age
5 days showed a GALT activity of 3% in the Beutler test
and slightly elevated Gal and Gal-1-P: 0.8 and 2.7 mmol/l,
respectively. At the time of recall (age 6 days) the patient
did not present any clinical symptoms, despite Gal
3.9 mmol/l and Gal-1-P 2.3 mmol/l. Urine galactitol at the
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c.1001_1002delinsT

1

0.0028
0.0038
1
p.(Arg333Trp)
c.997C>T

Note: Novel variants are depicted in bold. GnomAD v2.1.1, db SNP Database of single nucleotide polymorphisms. Position according to the reference sequence NM_00155.3.
Abbreviation: −, not found in GnomAD.
a
Allele number = 26 130.
b
Allele number = 251 000-283 000.
c
In cis with p.(Asn314Asp).
d
In cis with p.(Glu160del).
e
Homozygous patient.
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TABLE 1

time of recall was 1940 mmol/mol creatinine, which is elevated but lower than usually seen in patients with classical
galactosemia. Quantitative determination of GALT activity
in erythrocytes with 14C-labeled Gal-1-P substrate showed
an activity of 3% of normal (Table 3). The patient was classified as having a milder form of classical galactosemia and
had normal secretion of galactitol in urine during dietary
treatment.

4.4 | p.(Pro36=)

GnomAD (%)
Swedena

dbSNP

Polyphen 2

Provean

References
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The synonymous variant p.(Pro36=) (c.108G>C) was
detected in combination with p.(Gln188Arg). The patient was
re-called with a presumptive classical galactosemia. The
patient had a residual activity of 9% in the Beutler test and the
concentrations of Gal and Gal-1-P were 7.8 and 0.5 mmol/l,
respectively. Galactitol in urine was 9600 mmol/mol creatinine. The second DBS sample showed a GALT activity of
12% in the Beutler test. A prolonged incubation time in the
Beutler test from 3 to 6 hours showed a proportional increase
of fluorescence values over time. An increase in fluorescence
is not seen in patients with two null variants (Figure 1A).
In silico analysis predicted the synonymous variant p.
(Pro36=) to create a new acceptor splice site 32 base pairs
upstream of the authentic site and seven base pairs from the
variant. The splicing pattern for p.(Pro36=) was investigated
in mRNA isolated from leukocytes. The cDNA transcript,
when visualized on a 3% agarose gel after electrophoresis,
showed two different bands—one of normal and one of
shorter length (Figure 1B). Sanger sequencing of the shorter
PCR product confirmed the in silico prediction. The p.
(Pro36=) variant is classified as mild and the patient had normal secretion of galactitol in urine during dietary treatment.

4.5 | p.(Ala81Pro)
The variant p.(Ala81Pro) (c.241G>C) was found together
with p.(Gln188Arg). The screening sample taken at age
3 days showed a GALT activity of 8% in the Beutler test
and Gal and Gal-1-P levels were 0.3 and 1.9 mmol/l, respectively. The same low activity in the Beutler test was found
in the second DBS, with Gal and Gal-1-P levels of 0.6 and
1.4 mmol/l. Galactitol in urine was 1050 mmol/mol creatinine. GALT activity in erythrocytes with 14C-labeled Gal1-P was 10% of normal. A longer incubation in the Beutler
test from 3 to 6 hours showed a proportional increase of
fluorescence over time, indicating that the patient has an
ability to metabolize Gal-1-P to some extent, but at a slower
rate than healthy controls (Figure 1A). The p.(Ala81Pro)
variant is classified as mild and the patient had normal secretion of galactitol in urine without dietary treatment.

Note: Novel variants depicted in bold. Position according to reference sequence NM_00155.3.
a
BIA bacterial inhibition assay.
b
Not verified in parents.
c
Analyzed at arrival in Sweden.
d
Diagnosed in home country and on treatment.
e
Analyzed at age 4 days (second sampling).
f
Patients with Duarte galactosemia on nonrestricted diet.
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687 bp

Exon 2
Exon 2

1 hour

2 hour

Genotype

μkat/kg
Hb (%)

μkat/kg
Hb (%)

p.[=];[=]

9.8 (100)
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p.[(Arg25Pro)];[(Gln188Arg)]
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0.47 (2.6)
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0.08 (0.8)

p.[(Gln188Arg)];[(Arg333Trp)]

0.05 (0.5)

0.17 (0.9)
−0.05 (0)

Note: GALT activity measured in erythrocytes at time point 1 and 2 hours in two
patients with residual activity.

(A)

Exon 2
Exon 2

Ex 3
Exon 3

Exon 4

Exon 4

Exon 5

650 bp

Exon 4

Exon 5

(A)

Exon 4

Exon 5

(B)

Exon 5

(C)
(D)

F I G U R E 2 cDNA transcript after RT-PCR of the novel
synonymous variant p.(Pro109=). The transcripts were visualized on a
3% agarose gel. Lane 1 and 2, wild type, lane 3 patient homozygous for
p.(Pro109=), lane 4 size standard. (A) Insertion of intron
3, (B) skipping of 49 bp of exon 3 and insertion of intron 3, (C) wild
type, (D) skipping of exon 3

(B)
Galactose-1-phosphate uridyltransferase activity

Lane 4

Erythrocyte GALT activity

Exon 3

850 bp

Lane 3

TABLE 3

A
B
C
D

Lane 2

The synonymous variant p.(Pro109=) (c.327A>G), was
found in a homozygous state in one patient with classical
galactosemia and in compound heterozygous state together
with p.(Asn314Asp) in a D/G patient.
The patient, homozygous for this variant, had a GALT
activity of 7% in the Beutler test and Gal and Gal-1-P values
of 15.8 and 4.1 mmol/l, respectively. Urine galactitol was
markedly elevated, 17 700 mmol/mol creatinine. Quantitative
measurement of GALT activity in erythrocytes with 14Clabeled Gal-1-P showed an activity of 0.8% and 0.9% of normal after 1 and 2 hours of incubation, respectively (Table 3).
The second patient, who was compound heterozygous
for p.[(Pro109=)];[(Asn314Asp)], also had a GALT activity
of 7% in the Beutler test. The concentrations of Gal and Gal1-P were <0.1 and 0.93 mmol/l, respectively. The patient

has always been on an unrestricted diet and is classified as
having D/G.
According to in silico analysis, the synonymous variant
p.(Pro109=) is predicted to weaken the authentic donor site
in exon 3, a decline in BDGP score from 0.90 to 0.36. The
splicing pattern for p.(Pro109=) was investigated in mRNA
isolated from fibroblasts. The cDNA transcript, when visualized on a 3% agarose gel, showed four different bands which
were subjected to Sanger sequencing (Figure 2A). The
detection of a faint band of normal length probably explains

Lane 1

4.6 | p.(Pro109=)

40

650 bp

35
30
25

500 bp

20
15

400 bp

10
5

300 bp

0

3 hours

FIGURE 1

6 hours

(A) Relative increase in fluorescence seen over time for the novel variants p.(Pro36=) and p.(Ala81Pro). Both these variants are in
compound heterozygous state with p.(Gln188Arg) and analyzed with the Beutler assay. Fluorescence was measured at the time points 3 and 6 hours.
Samples from a healthy individual, p.[=];[=] and a patient who is compound heterozygous for p.[(Gln188Arg)];[=], 50% GALT-activity, were used
as controls. (B) cDNA transcript after RT-PCR of the novel synonymous variant p.(Pro36=). The transcripts were visualized on a 3% agarose gel
resulting in an additional 32 bp shorter product. Lane 1, size standard, lane 2, patient compound heterozygous for p.[(Gln188Arg)];[=], lane
3, patient compound heterozygous for p.[(Pro36=)];[(Asn314Asp)], lane 4, control (wild type)
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Mendelian inheritance in a family with four GALT alleles
Allele 1

Allele 2

GALT activity % of normal in erythrocytes

Patient

p.[(Leu71Phe);(Glu160del)]

p.(Gln353_Ala354ins18)

0.1

Mother

p.[=]

p.(Gln353_Ala354ins18)

50

Father

p.(Leu71Phe)

p.(Asn314Asp)

76

Sibling

p.(Asn314Asp)

p.(Gln353_Ala354ins18)

29

the presence of a low residual activity of GALT in erythrocytes. The p.(Pro109=) variant is classified as a less severe
variant of classical galactosemia.

4.7 | p.(Glu160del)
The novel in-frame variant, p.(Glu160del) (c.478_480delGAG),
was found in cis with p.(Leu71Phe) (c.211C>T). The patient
was previously found to carry a cryptic splice site variant p.
(Gln353_Ala354ins18) (c.1059+56C>T) in intron 10 on one
allele.20 The cryptic splice site variant leads to an insertion of
18 amino acid as determined at the cDNA level. Mendelian
inheritance estimation and GALT activity measurements were
performed in the family (Table 4). The result of the measurements of GALT activity was inconclusive until sequencing
analysis of the family was performed. Genetic analysis revealed,
that the father was compound heterozygous for p.(Leu71Phe)
and p.(Asn314Asp), the latter being the Duarte variant. The sibling was compound heterozygous for the D/G genotype, p.
[(Asn314Asp)];[(Gln353_Ala354ins18)]. The mother was carrier of the p.(Gln353_Ala354ins18). The p.(Glu160del) variant
was not found in the father or mother indicating that it was a de
novo mutation. According to the patient's phenotype, the in
frame variant p.(Glu160del), is most probably associated with
classical galactosemia.
Based on the father's genotype p.[(Leu71Phe)];[(Asn314Asp)]
and GALT activity of 76% of normal in erythrocytes, the variant
p.(Leu71Phe) is classified as benign. To our knowledge the variant p.(Leu71Phe) has not been described in patients with galactosemia (Table 1).

4.8 | c.508-29delT and c.508-2_509delAGAT
The variant c.508-29delT has previously been described in a
patient of Somali ancestry with classical galactosemia.29 The
authors speculated that the variant may affect a branch point
sequence in the GALT gene, resulting in a disruption of the
authentic splice site. In our cohort, the variant c.508-29delT
was found in a homozygous state in two patients of Somali
ancestry as well.
The novel variant c.508-2_509delAGAT deletes the last
two nucleotides in intron 5 and the two first nucleotides in
exon 6, compromising the authentic 30 acceptor site. This

variant was detected together with p.(Gln188Arg) in a
patient with classical galactosemia.
In silico analysis with BGDP of each of these variants
predicted the loss of the authentic 30 acceptor splice (BDGP score
0.93), while creating a cryptic splice site (BGDP score of 0.98).
We investigated the aberrant splicing in mRNA from fibroblasts of a patient homozygous for c.508-29delT and from
leukocytes of the patient heterozygous for the c.508-2_509delAGAT variant. Both variants activated the predicted cryptic
splice site, between nucleotides −68 and −67 upstream of c.508
(Supporting Information, Figures S1 and S2).

4.9 | Variants in cis with p.(Asn314Asp)
Due to the high allele frequency of the Duarte variant, it is
not uncommon to find the variant in cis with another galactosemia variant. In our study, the novel variant p.(Arg33Cys)
(c.97C>T) and the earlier described variant p.(Ala320Thr)
(c.958G>A)30 were found in cis with p.(Asn314Asp). Both
patients carry the common p.(Gln188Arg) variant on the second allele and have the classical phenotype.

5 | DISCUSSION
This is the first complete genetic study of patients with
GALT deficiency in a Scandinavian country. All known
patients, except one, are included in the survey. The birth
incidence of GALT deficiency in Sweden is approximately
1/100 000, which is the same as in France and Italy, but
lower than the reported incidence of 1/30 000-40 000 for
most other European countries.28,35,36
Thirty-three variants were detected in the Swedish galactosemia population, and of these 16 are unique for our cohort.
Fifteen are not found in HGMD or ARUP GALT database and
one has previously been published in 1993.20 Only a few variants are frequent, which agrees with reports from other countries.30,31,37,38 The most common variant, among Swedish
patients with classical galactosemia is p.(Gln188Arg) with an
allele frequency of 51%.
The missense variant, p.(Met142Lys), was one of the first
variants identified to cause galactosemia.16 Although it is
well described, this is the first time to our knowledge, that p.
(Met142Lys) is reported as the second most common variant
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in a population. Eight of the patients carrying this variant are
of Swedish or Norwegian origin, while the ninth is from
Lithuania.
Two novel variants were found in more than one patient,
the variants p.(Leu37Arg) and p.(Pro109=). The two
patients heterozygous for p.(Leu37Arg) carry the variants p.
(Met142Lys) and p.(Lys285Asn) on the second allele,
respectively. Both presented with severe clinical symptoms
before the initiation of treatment.
The Duarte variant, p.(Asn314Asp), is found in all
populations, albeit with different frequencies. According to
the database GnomAD the highest allele frequency is found
in South Asia (18%), as compared to an allele frequency of
9.4% in Europe (non-Finnish). The lowest frequency is found
in East Asia (0.9%). At least nine missense variants and four
nonsense variants have previously been described in cis with
the Duarte variant (Supplemental Table S3).28,30,31,39-42
The two complex variants p.(Arg33Cys;Asn314Asp) and p.
(Asn314Asp;Ala320Thr) in our population increase this group
to 15. These results demonstrate the importance of sequencing
the whole GALT gene and not only a panel including common
variants. If only a panel is analyzed and p.(Asn314Asp) is
included, there is a risk of misdiagnosis, as the p.(Asn314Asp)
variant frequently occurs in cis with more rare variants.
Occasionally, patients with D/G are recalled because of a
GALT activity <15% in the Beutler test. The patient who is
compound heterozygous for p.[(Ala81Pro)];[(Gln188Arg)]
was recalled due to a residual activity of 8%,which was the
same in the repeat sample, while Gal-1-P was only slightly
elevated. Genotyping detected the novel variant p.
(Ala81Pro). A disease-causing variant in the same codon p.
(Ala81Thr) (c.241G>A) has been described.32 To assist estimation of the pathogenicity of p.(Ala81Pro), the variant was
evaluated in PolyPhen-2, with the result “Benign,” in contrast to p.(Ala81Thr), which was denoted “Probably
damaging,” The variant p.(Ala81Pro) reduces GALT activity
in the Beutler test to the same extent as in classical galactosemia patients. Blood samples from the patient with this
mutation in combination with p.(Gln188Arg) still have the
ability to metabolize Gal-1-P, although at a slower rate than
samples from healthy controls. This was seen when measuring GALT activity quantitatively in erythrocytes as well as in
a prolonged Beutler test. We consequently estimate that the
variant p.(Ala81Pro) results in a severity equal to Duarte
galactosemia. The patient has been on a normal diet from
1 year of age, is close to 10 years old and has had a normal
development. All the patients with mild galactosemia have
had a normal secretion of galactitol after the newborn period.
The patient with the de novo mutation described here
illustrates the importance of sequencing the complete GALT
gene in all family members when the results of the measurement of GALT activity are inconclusive.

5.1 | Impact of synonymous variants
Synonymous variants in the GALT gene are common. The
ARUP GALT database and Exome Aggregation Consortium
(ExAC) (http://exac.broadinstitute.org, accessed 22 October
2018) contain 12 and 44 unique synonymous variants,
respectively. An additional seven variants are found in both
databases. Fifteen of the synonymous variants in the ARUP
GALT database are described as benign, whereas four are of
uncertain severity. After in-silico analysis of all 63 variants
in BDGP, only six variants were predicted to either abolish
or weaken an existing splice site or create a new splice site.
Included in the six synonymous variants, predicted to affect
splicing, are the three variants proven to be pathogenic: p.
(Pro36=), p.(Pro109=) and the earlier presumably benign
synonymous variant, p.(Gly338=) (c.1014C>G). The latter
has been shown to be disease-causing by activating an alternative splice donor site, resulting in the exclusion of
46 nucleotides at the end of exon 10.28 The two synonymous
variants described in this article both result in reduced
GALT activity. The variant p.(Pro36=) activates a new
acceptor splice site, excluding 32 nucleotides at the beginning of exon 2, giving a shorter protein. Amplification of
GALT cDNA carrying the p.(Pro109=) variant revealed the
presence of multiple fragments from RT-PCR (Figure 2A,
B). This strongly suggests that the p.(Pro109=) allele in this
patient generates a normal transcript, two longer and one
shorter transcript, supporting the idea that all four 5'splicing
sites, cryptic and normal are used.
Splice variants that generate both normal and abnormal
transcripts from the same allele are referred to as leaky.
The relative amounts of normal and aberrant splice products generated are important; the higher the levels of normal transcript, the milder the phenotype. The presence of
some normal transcript is probably generating the residual
GALT activity of approximately 1%, which is supported
by the 1- and 2-hour incubation of erythrocytes with 14Clabeled Gal-1-P and the somewhat milder phenotype of the
patient. Our results, together with the results of Bourton
et al 2012, strengthen the importance to evaluate the consequences of synonymous variants at the mRNA level,
especially if no other variants in the GALT gene are
detected.28
Classical galactosemia is a potentially progressive disease.4 Our experience from the three patients described in
this paper with some residual activity is that a GALT activity
of 1% is not enough to prevent severe symptoms before
diagnosis or to prevent long term complications when the
patient is on Gal restricted diet.
Sweden moved the sampling time from as early as possible after 72 hours, to as early as possible after 48 hours of
age in 2008. An important advantage of the earlier sampling
time is that patients are recalled at a younger age. This
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increases the chance of diagnosis and commencement of
treatment, before the development of life-threatening
symptoms.
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6 | CONCLUSI ON S
OR CI D
Classical galactosemia is a rare disease in Sweden affecting
1/100 000 newborn infants. Like in other countries only a
few variants in the GALT gene are frequent in the cohort. In
this study 16 of the 33 variants are novel including a probable de novo variant.
The variants p.(Pro36=) and p.(Pro109=) are two new
synonymous variants in the GALT gene proven to be pathogenic. This demonstrates the importance of evaluating the
consequences of synonymous variants in the GALT gene at
the cDNA level.
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